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BACKGROUND:  In  smoking  COPD  patients  the  bron-
choalveolar lavage (BAL) fluid contains high numbers
of  inflammatory  cells.  These  cells  might  produce
arachidonic acid (AA) metabolites, which contribute
to  inflammation  and  an  increased  bronchomotor
tone.
Aims: To investigate levels of AA metabolites in BAL
fluid, before and after inhaled glucocorticoid therapy:
fluticasone  propionate  (FP)  1mg  per  day,  or
placebo.
Methods:  A  double-blind  placebo  controlled  trial
lasting six months. COPD patients were selected by
clinical criteria and the presence of bronchial hyper-
responsiveness (BHR).  Lung  function  was  recorded
and  in  BAL  fluid  we  counted  cell  numbers  and
measured  LTB4,  LTC4/D4/E4,  PGE2,  6kPGF1a ,  PGF2a
and TxB2. A control group consisted of asymptomatic
smokers (n=6).
Results: Paired data were obtained from 9 FP treated
and  11  placebo  patients.  BAL  cells  were  almost
exclusively  alveolar  macrophages.  In  patients  and
controls both cellularity and levels of AA metabolites
were  equal.  Cell  numbers  did  not  change  after
treatment. Statistically  significant decreases after FP
therapy were noticed for PGE2 (30%), 6kPGF1a (41%)
and PGF2a (54%).
Conclusions: In COPD, the capability of inflammatory
cells to produce certain AA metabolites was decreased
after inhaled FP treatment. This result is discussed in
its relation to clinical effects, the influence of smok-
ing,  and  the  results  of  an  earlier,  similar  study  in
asthma patients.
Introduction
Leukotrienes  (LTs)  and  prostaglandins  (PGs)  are
mediators  of  inflammation  that  have  been  investi-
gated almost exclusively in asthma, but not in COPD.
These  metabolites  of  arachidonic  acid  (AA)  are
products of several inflammatory cells and part of the
mechanisms  leading  to  bronchoconstriction  and
increased bronchomotor tone. In chronic obstructive
pulmonary  disease  (COPD)  airway  narrowing  is
caused by several mechanisms, including mechanical
factors  (loss  of  elasticity  of  the  lung  parenchyma),
increased thickness of the  walls  of the  conducting
airways,  increased  bronchomotor  tone  and  intra-
luminal secretions.1,2 Increased numbers of alveolar
macrophages,  neutrophilic  granulocytes  and  CD8
positive  cells  constitute  the  main  burden  of  the
cellular infiltrate in the airway walls and alveoli. Their
secretory  products  cause  multiple  effects,  for
instance cell  influx  and cell  activation, but  also an
increase  of  the  contractile  status  of  the  smooth
muscles  in  the  small  bronchi.  Among  these  cell
products, AA metabolites are known for their potent
bronchoconstrictor activity.
Therefore,  we  hypothesized  that AA  metabolites
could also be detected in COPD and anti-inflamma-
tory treatment could influence their levels. Samples
of  BAL supernatant were collected at the start and
after six months of a double-blind trial comparing the
effect of fluticasone propionate (FP) with placebo, in
smoking  COPD  patients.  We  decided  to  study  a
subgroup of COPD patients, particularly those with
bronchial hyperresponsiveness (BHR), because these
patients  are  subject  to  an  even  more  accelerated
decline of their FEV1.3,4 This could indicate a severe
inflammatory infiltrate, increased levels of AA metabo-
lites  and  potentially  an  effect  of  an  inhaled  gluco-
corticoid.  Smokers  without  symptoms  and  with
normal lung function served as controls.
Material and methods
Patients
COPD patients were selected according to generally
accepted clinical  and  functional  criteria.5 Inclusion
criteria were: age between 40 and 70 years, current
smoker,  FEV1/iVC  ratio£ 70%  of  predicted  normal
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750 m g terbutaline, non-specific BHR – defined by a
PC20 histamine£ 8mg/ml – and negative skin tests for
standard  inhaled  allergens.  Reference  values  were
obtained from ECCS standards.6 The main exclusion
criteria were a history of asthma and recent respira-
tory  tract  infection. Any  anti-inflammatory  therapy,
including  corticosteroids,  non-steroidal  anti-inflam-
matory  drugs  and  theophyllines, was  discontinued.
Potential  candidates  for  this  study  were  informed
about the negative effects of smoking, and we offered
them  the  opportunity  to  participate  in  a  smoking-
cessation  program.  The  Hospital’s  Medical  Ethics
Committee  approved  the  study.  Written  informed
consent was obtained from all participants.
Design of the intervention study
We  performed  a  double-blind,  placebo-controlled
study  that  lasted  for  six  months.  Patients  were
randomly assigned to either twice-daily 500 m g FP or
placebo, which were delivered via a similar diskhaler.
The start of treatment was immediately after the first
bronchoscopy.  Bronchoscopy  was  repeated  at  the
end of the study. Follow-up visits were at intervals of
four weeks.
Bronchoscopy
The  procedure was  carried out  according to  inter-
national  guidelines.7 For  local  anaesthesia we  used
lidocaine spray and aerosolised oxybuprocaine. The
bronchoscope (Olympus BF 1T10) was advanced into
the  lateral  segment  of  the  middle  lobe,  in  wedge
position.  Lavage  was  performed  successively  with
1´ 40ml and 4´ 50ml sterile phosphate-buffered saline
(PBS) solution (Organon Teknika, Boxtel, The Nether-
lands)  at  body  temperature  (37°C)  and  pH  7.4.
Aliquots were aspirated in two siliconized specimen
traps, one for the first ‘bronchoalveolar fraction’ after
40ml PBS and the second ‘alveolar fraction’ for the
recovery of  the  4´ 50ml  PBS. The  lavage fluid  was
transported to the laboratory on ice and processed
immediately. The recovery of the first, bronchoalveo-
lar fraction appeared to be low and insufficient  for
performing the desired experiments.
Processing of BAL fluid
After  measurement  of  volume,  the  BAL  fluid  was
filtered through sterile nylon gauzes and centrifuged
at 400´ g at 4°C for 5min. The cell pellet was washed
in PBS supplemented with 0.5% bovine serum albu-
min. The total cell number in the BAL cell suspension
was counted in a Coulter Counter Model ZM (Coulter
Electronics,  Hialeah,  FL,  USA)  and  viability  was
assessed by  cellular  exclusion  of  trypan blue. With
FACScan flow-cytometry (Becton Dickinson, San Jose,
CA,  USA)  we  analyzed  CD3+ T-cells.  Immunocy-
tochemistry of  cytospins  was  carried  out  with  the
APAAP  (alkaline  phosphatase anti-alkaline  phospha-
tase) method and the monoclonal antibodies CD68
(alveolar macrophages), CD15 (VIM-D5, neutrophils)
and BMK–13 (eosinophils). Two independent obser-
vers counted at least 300 cells in each cytospin.
Determination of concentrations of AA
metabolites
In an earlier publication this has been described in
more detail.8 In summary, immediately after the BAL
procedure,  20ml  of  supernatant was  processed on
C18  SepPak  cartridges  (Millipore,  Bedford,  MA),
eluated  with  2.5ml  methanol  and  stored  at  –80°C
until analysis. Samples of 200 m l BAL eluted fluid were
pipetted into polypropylene tubes and dried with a
Savant sample concentrator. After dissolving in 300 m l
assay  buffer,  levels  of  thromboxane B2 (TxB2)  and
LTB4 were determined by means of a [3H] RIA with
antisera from Advanced Magnetics Inc. (Cambridge,
MA) and [3H]  labelled  compounds from Amersham
International (Buckinghamshire, UK). Levels of PGE2
and  PGF2a were  determined  with  commercially
available [3H] kits (Amersham, UK) and 6kPGF1a with
a  [125I]  RIA  kit  (Du  Pont  de  Nemours,  Dreieich,
Germany),  according to  the manufacturer’s instruc-
tions. LTC4/D4/E4 was measured at room temperature
in  a  microtitre  enzyme  immunoassay  according  to
protocol  (Biotrak, Amersham,  UK). The  cross  reac-
tivity of the LTC4 antibody with LTD4 was 100% and
with LTE4, 30%. Cross reactivities for the other assays
to related compounds were negligible or less than 2%
at B/Bo 50%.
Statistics
Data are expressed as mean±SD or as median (range),
depending  on  distribution  of  data.  Differences
between patient groups were tested with either the
(unpaired) Student t-test or the Mann–Whitney test,
depending upon distribution of data. Pre- and post-
intervention  data  were  tested  for  significant  differ-
ence with the paired t-test or the Wilcoxon signed
rank  test.  Statistical  significance  was  considered at
p<0.05.
Results
From  the  initial  23  participants in  the  intervention
study, paired results were obtained from 9 FP patients
and from  12  patients with placebo. The reason for
missing  paired  data  were  insufficient  recovery  of
either  BAL  fluid  or  BAL  cells.  Characteristics  of
patients  (n=21)  and  controls  are  listed  in Table  1.
Baseline  characteristics  of  the  FP  and  the  placebo
group did not differ significantly. The COPD patients
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disease and severe BHR. FEV1%pred and PC20 were
within  the range  of  normal values in  the  group  of
asymptomatic smokers, due to selection.
Compliance with study medication was high. The
percentage  of  returned  used  blisters  (which  con-
tained FP or placebo) was 92.5 in the FP and 92.7 in
the placebo group. In the placebo group, mean FEV1
declined from 61.4 %pred at the start of the trial to
52.0 %pred after 6 months. On the other hand, in the
FP treated patients, lung function remained unchan-
ged;  mean  FEV1:  66.4  and  68.1%pred,  respectively.
This  treatment  effect  was  statistically  significant
(p<0.05, rmANOVA test), and considered as a bene-
ficial effect of FP treatment. Parameters of BHR were
not influenced by FP treatment.
Immunocytology
BAL fluid  recovery was  higher  in  controls as  com-
pared to the COPD patients (Table 2). Mean total cell
number of the BAL at the start of the trial was 49´ 106
for  FP  treated  patients  and  44´ 106 in  the  placebo
group (Table 2, no statistical significant difference).
Small changes were noticed in the BAL cell numbers
at  the  end of the trial,  which  were not  significant
(Table  2).  The  percentages  of  fluid  recovery,  cell
viability and cells types were not statistically different
between both patient groups at baseline, and did not
change  significantly  after  6  months  of  intervention
(Table 2). The low number of eosinophils indicates
that COPD was stable in nature.2
Arachidonic Acid metabolites
Table 3 shows the levels of protein, albumin and AA
metabolites  at  the  start  and  after  six  months  of
intervention, which consisted of either FP inhalation
or placebo. The results of the initial measurements in
the  FP-treated  patients  and  the  placebo  group  are
comparatively  equal  (p>0.05,  Mann–Whitney  test).
There are also no significant differences when com-
paring the COPD patients with the controls. Statis-
tically  significant  differences  (comparing  post-  and
pre-intervention results) were found in the FP-treated
patients with  regard to PGE2,  6kPGF1a and  PGF2a
(p<0.05, Wilcoxon signed rank test). After correction
for protein levels, the results from the statistical tests
were similar and also significant for the same three
mediators (data not shown). The change of levels of
6kPGF1a and PGF2a differed significantly from that in
the  placebo  group  [treatment  effect]  (p<0.05, Wil-
coxon signed rank test).
Discussion
In  a subgroup  of  COPD patients, particularly  those
with  bronchial  hyperresponsiveness,  we  were  able
to  measure  levels  of  cyclooxygenase  and  5-lipox-
ygenase  products  in  BAL  fluid  and  observed  sig-
Arachidonic acid metabolites in COPD
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Table 1. Patient characteristics
Fluticasone propionate Placebo Asymptomatic smokers
N 9  12  6 
Age, years 54 ± 8 56 ± 8 44 ± 9
Cigarettes/day 15 ± 8 16 ± 7 21 ± 10
Pack years 25 ± 12 26 ± 10 23 ± 12
FEV1%pred 66 ± 13 61 ± 12 93 ± 11
FEV1 reversibility, % 5.3 ± 3.7 5.6 ± 2.7 4.0 ± 3.0
PC20 histamine,mg/ml 2.6 ± 2.4 0.8 ± 0.6 >8 
Mean±SD
Table 2. Characteristics of bronchoalveolar lavage
Fluticasone propionate
Start 6 months
Placebo
Start 6 months
Asymptomatic
smokers
Fluid recovery, % 55 ± 14 57 ± 14 55 ± 15 50 ± 19 69 ± 2.2
Cell number, ´ 10
6 49 ± 24 47 ± 31 44 ± 27 40 ± 23 53 ± 27
Cell viability, % 62 ± 12 66 ± 12 70 ± 13 67 ± 12 66 ± 14
CD68
+ macrophages, % 93 ± 8 94 ± 4 94 ± 4 91 ± 7 93 ± 7
CD15
+ granulocytes, % 2.9 ± 2.5 2.8 ± 2.7 2.8 ± 2.7 3.6 ± 6.4 1.7 ± 1.6
BMK13
+ eosinophils, % 0.6 ± 0.4 0.5 ± 0.4 0.5 ± 0.4 1.0 ± 1.3 0.9 ± 0.1
CD3
+ T-cells, % 1.3 ± 1.9 0.7 ± 0.6 3.8 ± 4.8 5.9 ± 5.2 1.8 ± 1.9
Mean ± SDT
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24 Mediators of Inflammation · Vol 10 · 2001nificant decreases of three out of six mediators after
inhaled fluticasone propionate therapy, in a placebo
controlled trial that lasted for six months (Table 3).
Arachidonic acid  metabolites have gained attention
in asthma, in which they play an important role as
mediators of inflammation with bronchoconstriction
as the most important clinical effect. In  a previous
study  in our institution concerning asthma patients
we  have  used  the  same  techniques  for  collecting
BAL fluid  and measuring  levels  of AA metabolites.9
These  patients  had  a  similar  degree  of  BHR  (as
expressed by PC20) compared to the COPD patients
in the present study. However, these asthma patients
had  a  history  consistent  with  asthma,  they  had
allergic reactions for common inhaled allergens and
were non-smokers. LTC4/D4/E4 levels were compara-
ble,  whereas  levels  of  TxB2,  PGE2 and  6kPGF1a
were, respectively, approximately 10-, 5- and 15-fold
higher in COPD as compared to asthma. The number
of  cells  in  the  BAL  fluid  was,  however,  about  five
times  higher  in  COPD  as  compared  to  asthma.
Taking this into account, it appears that cell  secre-
tory activity with regard to LTC4/D4/E4 is higher in
asthma. This is feasible because asthma is an allergic
inflammatory  disease, whereas in  COPD there  is  a
non-specific inflammatory infiltrate. The production
of  LTC4/D4/E4 is  almost  exclusively  attributed  to
mast cells, which are numerous in the airway walls
of asthma patients, whereas they are hardly detect-
able  in  COPD.  On  the  other  hand,  inflammatory
cells in COPD seem to produce higher amounts of
TxB2 and  6kPGF1a . The  most  obvious  explanation
seems to be that this is induced by cigarette smok-
ing. In one other study we have shown that levels of
TxB2 and  PGF2a in  BAL  fluid  were  significantly
elevated  in  smokers  as  compared  to  non-smokers,
and  this  correlated  with  packyears.8 Smoking  also
increased the pentagastrin-stimulated gastric luminal
release of TxB2 and PGF2a .10 In  the present study,
we  have  compared  levels  of  these  mediators  in
smoking COPD patients with the levels in a control
group  which  consisted  of  asymptomatic  smokers
with normal lung function and negative allergy tests.
There were no significant differences. These results
indicate  that  smoking  (and  not  some  mechanism
specific  for  COPD)  could  be  the  single  or  most
important  stimulus  for  an  inflammatory  infiltrate
with  high  levels  of  certain  cyclooxygenase
products.11
Fluticasone  propionate  (FP)  had  no  significant
effect on BAL cellularity or on protein and albumin
levels (Table 2). Apparently, the influx and the survival
of  cells  were  not  affected  by  this  potent  topical
glucocorticoid. FP also did not influence the levels of
the  leukotrienes.  However,  cell  secretory  activity,
particularly  the  production  of  PGE2,  6kPGF1a and
PGF2a , was inhibited as their levels were decreased
after 6 months exposure to FP (Table 3).
In the above mentioned previous study of asthma
patients the same dose of FP was used.9 From the AA
metabolites  in  asthma,  only  PGD2 decreased  sig-
nificantly. Levels of PGF2a were not measured in that
study. One other study in asthma patients also showed
lower  levels  of  PGD2 in  BAL  fluid  after  inhaled
glucocorticoid therapy.12 It  was  concluded that,  in
asthma, FP downregulated the capability of mast cells,
and perhaps also of alveolar macrophages, to produce
PGD2. From our present study in COPD patients we
conclude  that  FP  causes  downregulation  of  the
capability of alveolar macrophages to produce certain
prostaglandins.
In  the  present  study,  the  statistically  significant
clinical effect of FP treatment in COPD patients with
BHR was not a reduction of any parameter related to
BHR, but the course of the FEV1: it decreased in the
placebo group, whereas it remained stable in the FP-
treated patients. So, in the placebo group the ongoing
inflammation  made airway obstruction  worse. Anti-
inflammatory  therapy  with  FP  obliterated  FEV1
decline, and one of the mechanisms underlying this
effect could be the reduction of levels of AA metabo-
lites, particularly PGF2a . PGF2a has strong broncho-
constrictor activity through a direct effect on airway
receptors  and  indirectly  through  cholinergic-medi-
ated  bronchoconstriction.13 Reduction  of  its  level
could diminish bronchomoter tone. We also observed
a significant decrease in the levels of 6kPGF1a and
PGE2. 6kPGF1a is derived from PGI2, which is, like
PGE2, a mediator with, amongst others, a bronchodi-
latory effect. Apparently, the activity of these PGs in
COPD is less as compared to the activity of PGF2a . In
murine  lower  airways  PGF2a was  the  most  potent
bronchial  muscle  constrictor.14 Alternatively,  other
inflammatory mechanisms could be more important
for  explaining  the  clinical  effect  of  FP  which  we
observed in this particular group of COPD patients.
In  conclusion,  the  ongoing  inflammation  with,
amongst others, high concentrations of PGF2a made
airway  obstruction  worse,  whereas  inhibition  of
PGF2a production  by  FP  seems  to  be  one  of  the
mechanisms  leading  to  preservation  of  lung
function.
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